MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Longboard Pharmaceuticals Inc

Healthcare US LBPH

38.0USD
0.99(2.67%)

Last update at 2024-07-11T14:58:00Z

Day Range

36.4938.49
LowHigh

52 Week Range

3.6028.15
LowHigh

Fundamentals

  • Previous Close 37.01
  • Market Cap730.95M
  • Volume208150
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-62.90200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.25

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -43.94500M -27.79700M -14.40000M
Minority interest - - -
Net income -43.09200M -27.73300M -14.40000M
Selling general administrative 10.16M 8.06M 9.77M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.00500M 0.00100M -
Ebit -44.80300M -27.83900M -14.40000M
Ebitda -44.79800M -27.83800M -14.40000M
Depreciation and amortization 0.00500M 0.00100M -
Non operating income net other -0.52800M - -
Operating income -44.79800M -27.83900M -14.40000M
Other operating expenses 44.80M 27.84M 14.40M
Interest expense 0.84M 0.04M 0.00000M
Tax provision - - -
Interest income 0.84M 0.06M -
Net interest income 0.84M 0.06M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense -0.85300M -0.06400M -
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 44.80M 27.84M 14.40M
Cost of revenue - - -
Total other income expense net 0.85M 0.04M -
Discontinued operations - - -
Net income from continuing ops -44.48900M -27.79700M -14.40000M
Net income applicable to common shares -43.94500M -27.79700M -14.40000M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 50.70M 70.62M 108.95M 56.24M
Intangible assets - - - -
Earning assets - - - -
Other current assets 1.72M 2.25M 1.66M 0.05M
Total liab 9.77M 9.15M 5.63M 3.13M
Total stockholder equity 40.92M 61.47M 103.32M 53.10M
Deferred long term liab - - - 0.88M
Other current liab 8.77M 7.10M 0.34M 1.92M
Common stock 0.00200M 0.00100M 0.00100M -
Capital stock 0.00200M 0.00100M 0.00100M 55.80M
Retained earnings -140.56400M -86.14200M -42.19700M -14.40000M
Other liab - - - -
Good will - - - -
Other assets 0.00000M 0.03M 0.03M 0.88M
Cash 14.33M 10.78M 66.35M 55.32M
Cash and equivalents - - - -
Total current liabilities 9.77M 8.76M 5.44M 3.13M
Current deferred revenue -0.47500M - 3.74M -
Net debt -13.85600M -10.03500M -65.82200M -55.31600M
Short term debt 0.47M 0.36M 0.34M -
Short long term debt - - - -
Short long term debt total 0.47M 0.74M 0.52M -
Other stockholder equity 181.56M 148.30M 36.73M 11.71M
Property plant equipment - 0.00900M 0.54M -
Total current assets 50.22M 69.84M 108.38M 55.36M
Long term investments - 0.03M - -
Net tangible assets - 61.85M 103.32M -2.69200M
Short term investments 34.17M 56.81M 40.38M -
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 1.00M 1.31M 1.03M 1.21M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.07800M -0.69200M -0.16400M -
Additional paid in capital - - - -
Common stock total equity - 0.00100M - -
Preferred stock total equity - - - -
Retained earnings total equity - -86.14200M - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - 0.03M 0.03M 0.88M
Deferred long term asset charges - - - -
Non current assets total 0.48M 0.78M 0.57M 0.88M
Capital lease obligations 0.47M 0.74M 0.52M -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -17.06400M -40.70000M -40.70000M
Change to liabilities 1.38M -0.18500M 1.21M
Total cashflows from investing activities -17.06400M -40.71600M -40.71600M
Net borrowings -0.44400M - -
Total cash from financing activities -0.44400M 76.45M 58.76M
Change to operating activities 2.84M 1.15M 1.24M
Net income -43.94500M -27.79700M -14.40000M
Change in cash -55.57100M 11.03M 55.32M
Begin period cash flow 66.35M 55.32M 0.00000M
End period cash flow 10.78M 66.35M 55.32M
Total cash from operating activities -38.06300M -24.70500M -3.44200M
Issuance of capital stock 0.00000M 84.77M 56.00M
Depreciation 0.00500M 0.00100M 0.00100M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock 0.00000M -0.00100M -
Other cashflows from financing activities -0.44400M -8.32200M 58.76M
Change to netincome 2.66M 2.12M 8.51M
Capital expenditures 0.00000M 0.02M 0.02M
Change receivables - - -
Cash flows other operating 1.74M - -
Exchange rate changes - - -
Cash and cash equivalents changes -55.57100M - -
Change in working capital 3.12M 0.97M 2.45M
Stock based compensation 2.66M 1.97M 8.51M
Other non cash items 0.10M 0.16M -
Free cash flow -38.06300M -24.72100M -3.44200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
LBPH
Longboard Pharmaceuticals Inc
0.99 2.67% 38.00 - - - 18.23 -12.3027
NVO
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals Inc

4275 Executive Square, La Jolla, CA, United States, 92037

Key Executives

Name Title Year Born
Mr. Kevin R. Lind Pres, CEO, Sec. & Director 1976
Ms. Brandi L. Roberts CPA, M.B.A. Chief Financial Officer 1974
Mr. Chadwick J. Orevillo MPH VP & Head of Operations NA
Megan E. Knight Head of Investor Relations NA
Mr. Steven W. Spector J.D. Head of Bus. Devel. & Gen. Counsel 1965
Dr. Anne M. Danks VP & Head of Preclinical Devel. NA
Dr. Jodi Parsons VP & Head of Regulatory Affairs NA
Dr. Randall E. Kaye M.D. Chief Medical Officer 1962
Gus Cardenas VP & Head of Quality Assurance NA
Dr. Marco Peters Ph.D. VP & Head of Translational Science NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.